Development of a kinetic model and calculation of radiation dose estimates for sodium iodide-{sup 131}I in athyroid individuals
The treatment for some thyroid carcinomas involves surgically removing the thyroid gland and administering the radiopharmaceutical Sodium iodide-{sup 131}I (NaI). A diagnostic dose of NaI is given to the patient to determine if remnant tissue from the gland remains or larger doses are administered in order to treat the malignant tissue. Past research regarding NaI uptake and retention in euthyroid individuals (normal functioning thyroid) reveal that radioiodine concentrates mainly in the thyroid tissue and the remaining material is excreted from the body. The majority of radioiodine in athyroid (without thyroid) individuals is also eliminated from the body; however, there has been recent evidence of a long-term retention phase for individuals with no radioiodine concentrating tissue. The general purpose of this study was to develop a kinetic model and estimate the absorbed dose to athyroid individuals regarding the distribution and retention of NaI.
- Research Organization:
- Colorado State Univ., Fort Collins, CO (United States)
- Sponsoring Organization:
- USDOE Assistant Secretary for Environment, Safety, and Health, Washington, DC (United States)
- DOE Contract Number:
- AC05-76OR00033
- OSTI ID:
- 672129
- Report Number(s):
- DOE/OR/00033--T765; ON: DE97053797
- Country of Publication:
- United States
- Language:
- English
Similar Records
Mammary radioiodine accumulation due to functional sodium iodide symporter expression in a benign fibroadenoma
Fetal radiation dose estimates for I-131 sodium iodide in cases where conception occurs after administration